Download PDF
Thromb Haemost 1998; 79(06): 1191-1198
DOI: 10.1055/s-0037-1615039
Rapid Communication
Schattauer GmbH

On the Mechanism of Plasmin-induced Aggregation of Human Platelets: Implication of Secreted von Willebrand Factor

S. Rabhi-Sabile
1   From the INSERM U.353, Hôpital Saint-Louis, Paris, France
,
C. de Romeuf
2   Laboratoire de Recherche sur l’Hémostase, Laboratoire Français du Fractionnement et des Biotechnologies, Lille, France
,
D. Pidard
1   From the INSERM U.353, Hôpital Saint-Louis, Paris, France
› Author AffiliationsSupported by a fellowship from the Association Sanofi Thrombose pour la Recherche (S. R.-S.), by the Centre National de la Recherche Scientifique (D. P.), and by the Institut National de la Santé et de la Recherche Médicale, Paris, France
Further Information

Publication History

Received 14 July 1997

Accepted after revision 25 February 1998

Publication Date:
07 December 2017 (online)

    Permissions and Reprints

Summary

Plasmin triggers a strong metabolic activation in human platelets, leading to shape change and granule exocytosis. However, its capacity to induce cell aggregation remains discussed and, when observed, this aggregation is preceded by a remarkable lag phase. We have thus investigated the effect of plasmin on the adhesive proteins which can be secreted by isolated platelets and mediate cell-to-cell interactions, but are also substrates for the enzyme. Immunoblot analysis of fibrinogen (Fg), thrombospondin-1 (TSP-1), fibronectin (Fn) and von Willebrand factor (vWf) was performed on extracts of platelets exposed under stirring to increasing concentrations of plasmin for up to 10 min at 37° C. Under conditions leading to formation of large aggregates, Fg, Fn and TSP-1 are extensively degraded concomitantly with their secretion, and readily lost from the surface of aggregated cells. Part of the monomers in the platelet vWf are cleaved during secretion into two main fragments with M r ≈180,000 and ≈145,000. However, multimer distribution analysis shows only a slight decrease in the very high molecular weight multimers, and most of the fragmented as well as intact vWf remains associated with the platelet surface when aggregation is maximal. That indeed vWf largely supports plasmin-induced aggregation is suggested by the observation that platelets from a patient with type 3 von Willebrand’s disease, who totally lacks vWf, show little aggregation in response to the enzyme. Finally, plasmin-induced aggregation can be totally inhibited by antagonists of the αIIbβ3 integrin. The present study thus indicates a major role for secreted vWf in platelet aggregation induced by plasmin, through its likely interaction with the multifunctional receptor αIIbβ3.

Presented in part at the European Platelet Group Meeting, Erfurt, Germany, May 1996

 

  • References

  • 1 Anglès-Cano E. Overview on fibrinolysis: plasminogen activation pathways on fibrin and cell surfaces. Chem Phys Lipids 1994; 67/68: 353-62.
    CrossrefPubMedGoogle Scholar
  • 2 Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-24.
    PubMedGoogle Scholar
  • 3 Coller BS. Platelets in cardiovascular thrombosis and thrombolysis. In: The Heart and Cardiovascular System. 2nd edition. Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE eds. Raven Press; New York: 1992. pp 219-73.
    Google Scholar
  • 4 Pasche B, Ouimet H, Francis S, Loscalzo J. Structural changes in platelet glycoprotein IIb/IIIa by plasmin: determinants and functional consequences. Blood 1994; 83: 404-14.
    PubMedGoogle Scholar
  • 5 Hoffmann JJML, Janssen WCM. Interactions between thrombolytic agents and platelets: effects of plasmin on platelet glycoproteins Ib and IIb/IIIa. Thromb Res 1992; 67: 711-9.
    CrossrefPubMedGoogle Scholar
  • 6 Federici AB, Berkowitz SD, Zimmerman TS, Mannucci PM. Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction. Blood 1992; 79: 38-44.
    PubMedGoogle Scholar
  • 7 Schafer AI, Maas AK, Ware JA, Johnson PC, Rittenhouse SE, Salzman EW. Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin. J Clin Invest 1986; 78: 73-9.
    CrossrefPubMedGoogle Scholar
  • 8 Penny WF, Ware JA. Platelet activation and subsequent inhibition by plasmin and recombinant tissue-type plasminogen activator. Blood 1992; 79: 91-8.
    PubMedGoogle Scholar
  • 9 Schafer AI, Adelman B. Plasmin inhibition of platelet function and of arachidonic acid metabolism. J Clin Invest 1985; 75: 456-61.
    CrossrefPubMedGoogle Scholar
  • 10 Nakamura K, Kimura M, Fenton II JW, Andersen TT, Aviv A. Duality of plasmin effect on cytosolic free calcium in human platelets. Am J Physiol 1995; 268: C958-67.
    CrossrefPubMedGoogle Scholar
  • 11 Blockmans D, Deckmyn H, Van den Hove L, Vermylen J. The effects of plasmin on platelet function. Platelets 1996; 7: 139-48.
    CrossrefPubMedGoogle Scholar
  • 12 Loscalzo J, Vaughan DE. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest 1987; 79: 1749-55.
    CrossrefPubMedGoogle Scholar
  • 13 Marguerie GA, Ginsberg MH, Plow EF. The platelet fibrinogen receptor. In: Platelets in Biology and Pathology III. MacIntyre DE, Gordon JL. eds. Elsevier Science Publisher BV; Amsterdam: 1987. pp 95-125.
    Google Scholar
  • 14 Peerschke EIB. Events occuring after thrombin-induced fibrinogen binding to platelets. Semin Thromb Hemost 1992; 18: 34-43.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Silverstein RL, Leung LLK, Nachman RL. Thrombospondin: a versatile multifunctional glycoprotein. Arteriosclerosis 1986; 6: 245-53.
    CrossrefPubMedGoogle Scholar
  • 16 Dixit VM, Haverstick DM, O’Rourke K, Hennessy SW, Broekelmann TJ, McDonald JA, Grant GA, Santoro SA, Frazier WA. Inhibition of platelet aggregation by a monoclonal antibody against human fibronectin. Proc Natl Acad Sci USA 1985; 82: 3844-8.
    CrossrefPubMedGoogle Scholar
  • 17 Gralnick HR, Williams SB, McKeown LP, Magruder L, Hansmann K, Vail M, Parker RI. Platelet von Willebrand Factor. Mayo Clin Proc 1991; 66: 634-40.
    CrossrefPubMedGoogle Scholar
  • 18 Ruggeri ZM. von Willebrand Factor. J Clin Invest 1997; 99: 559-64.
    CrossrefPubMedGoogle Scholar
  • 19 Peerschke EIB. Adhesive protein expression on thrombin-stimulated platelets: time-dependent modulation of anti-fibrinogen, -fibronectin, and -von Willebrand factor antibody binding. Blood 1992; 79: 948-53.
    PubMedGoogle Scholar
  • 20 Ruggeri ZM, De Marco L, Gatti L, Bader R, Montgomery RR.. Platelets have more than one binding site for von Willebrand factor. J Clin Invest 1983; 72: 1-12.
    CrossrefPubMedGoogle Scholar
  • 21 Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie GA, Ginsberg MH. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci USA 1985; 82: 8057-61.
    CrossrefPubMedGoogle Scholar
  • 22 Parker RI, Gralnick HR. Identification of platelet glycoprotein IIb/IIIa as the major binding site for released platelet-von Willebrand factor. Blood 1986; 68: 732-6.
    PubMedGoogle Scholar
  • 23 Watkins SC, Raso V, Slayter HS. Immunoelectron-microscopic studies of human platelet thrombospondin, Von Willebrand factor, and fibrinogen redistribution during clot formation. Histochem J 1990; 22: 507-18.
    CrossrefPubMedGoogle Scholar
  • 24 Heilmann E, Hourdillé P, Pruvost A, Paponneau A, Nurden AT. Thrombin-induced platelet aggregates have a dynamic structure. Time-dependent redistribution of glycoprotein IIb-IIIa complexes and secreted adhesive proteins. Arterioscler Thromb 1991; 11: 704-18.
    CrossrefPubMedGoogle Scholar
  • 25 Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Hellums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988; 71: 1366-74.
    PubMedGoogle Scholar
  • 26 Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I, Sakai K, Ruggeri ZM. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-40.
    CrossrefPubMedGoogle Scholar
  • 27 Frojmovic MM, Kasirer-Friede A, Goldsmith HL, Brown EA. Surface-secreted von Willebrand factor mediates aggregation of ADP-activated platelets at moderate shear stress: facilitated by GPIb but controlled by GPIIb-IIIa. Thromb Haemost 1997; 77: 568-76.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 De Marco L, Girolami A, Zimmerman TS, Ruggeri ZM. Von Willebrand factor interaction with the glycoprotein IIb/IIIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest 1986; 77: 1272-7.
    CrossrefPubMedGoogle Scholar
  • 29 Kurkinen M, Vartio T, Vaheri A. Polypeptides of human plasma fibronectin are similar but not identical. Biochim Biophys Acta 1980; 624: 490-8.
    CrossrefPubMedGoogle Scholar
  • 30 Doolittle RF. Fibrinogen and fibrin. In: Haemostasis and Thrombosis. Bloom AL, Thomas DP. eds. Churchill Livingstone; New York: 1981. pp 163-91.
    Google Scholar
  • 31 Lawler JW, Slayter HS. The release of heparin binding peptides from platelet thrombospondin by proteolytic action of thrombin, plasmin and trypsin. Thromb Res 1981; 22: 267-79.
    CrossrefPubMedGoogle Scholar
  • 32 Berkowitz SD, Dent J, Roberts J, Fujimura Y, Plow EF, Titani K, Ruggeri ZM, Zimmerman TS. Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin. J Clin Invest 1987; 79: 524-31.
    CrossrefPubMedGoogle Scholar
  • 33 Rabhi-Sabile S, Pidard D. Exposure of human platelets to plasmin results in the expression of irreversibly active fibrinogen receptors. Thromb Haemost 1995; 73: 693-701.
    PubMedGoogle Scholar
  • 34 Legrand C, Dubernard V, Nurden AT. Studies on the mechanism of expression of secreted fibrinogen on the surface of activated human platelets. Blood 1989; 73: 1226-34.
    PubMedGoogle Scholar
  • 35 Katayama M, Hino F, Odate Y, Goto S, Kimizuka F, Kato I, Titani K, Sekiguchi K. Isolation and characterization of two monoclonal antibodies that recognize remote epitopes on the cell-binding domain of human fibronectin. Exp Cell Res 1989; 185: 229-36.
    CrossrefPubMedGoogle Scholar
  • 36 Nishibuko T, Christophe O, Lavergne J-M, Obert B, Nonami K, Takahashi Y, Yoshioka A, Meyer D, Girma J-P. Abnormal proteolytic processing of von Willebrand factor Arg611Cys and Arg611His. Thromb Haemost 1997; 77: 174-82.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Hilbert L, Gaucher C, de Romeuf C, Horellou MH, Vink T, Mazurier C. Leu697→Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease. Blood 1994; 83: 1542-50.
    PubMedGoogle Scholar
  • 38 Legrand C, Thibert V, Dubernard V, Bégault B, Lawler J. Molecular requirements for the interaction of thrombospondin with thrombin-activated human platelets: modulation of platelet aggregation. Blood 1992; 79: 1995-2003.
    PubMedGoogle Scholar
  • 39 Pidard D, Montgomery RR, Bennett JS, Kunicki TJ. Interaction of AP-2, a monoclonal antibody specific for the human platelet glycoprotein IIb-IIIa complex, with intact platelets. J Biol Chem 1983; 258: 12582-6.
    PubMedGoogle Scholar
  • 40 Chuntharapai A, Bodary S, Horton MA, Jin Kim K. Blocking monoclonal antibodies to αVβ3 integrin: a unique epitope of αVβ3 integrin is present on human osteoclasts. Exp Cell Res 1993; 205: 345-52.
    CrossrefPubMedGoogle Scholar
  • 41 Rabhi-Sabile S, Pidard D, Lawler J, Renesto P, Chignard M, Legrand C. Proteolysis of thrombospondin during cathepsin-G-induced platelet aggregation: functional role of the 165-kDa carboxy-terminal fragment. FEBS Lett 1996; 386: 82-6.
    CrossrefPubMedGoogle Scholar
  • 42 Sadler JE, Matsushita T, Dong Z, Tuley EA, Westfield LA. Molecular mechanism and classification of von Willebrand disease. Thromb Haemost 1995; 74: 161-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J 1995; 9: 939-45.
    CrossrefPubMedGoogle Scholar
  • 44 Kimura M, Andersen TT, Fenton II JW, Bahou WF, Aviv A. Plasmin-platelet interaction involves cleavage of functional thrombin receptor. Am J Physiol 1996; 271: C54-60.
    CrossrefPubMedGoogle Scholar
  • 45 Michelson AD, Barnard MA. Plasmin-induced redistribution of platelet glycoprotein Ib. Blood 1990; 76: 2005-10.
    PubMedGoogle Scholar
  • 46 Cramer EM, Lu H, Caen JP, Soria C, Berndt MC, Tenza D. Differential redistribution of platelet glycoproteins Ib and IIb-IIIa after plasmin stimulation. Blood 1991; 77: 694-9.
    PubMedGoogle Scholar
  • 47 Nurden P, Humbert M, Piotrowicz RS, Bihour C, Poujol C, Nurden AT, Kunicki TJ. Distribution of ligand-occupied αIIbβ3 in resting and activated human platelets determined by expression of a novel class of ligand-induced binding site recognized by monoclonal antibody AP6. Blood 1996; 88: 887-99.
    PubMedGoogle Scholar
  • 48 Lopez-Fernandez MF, Ginsberg MH, Ruggeri ZM, Batlle FJ, Zimmerman TS. Multimeric structure of platelet factor VIII/von Willebrand factor: the presence of larger multimers and their reassociation with thrombin-stimulated platelets. Blood 1982; 60: 1132-8.
    PubMedGoogle Scholar
  • 49 Kunicki TJ, Montgomery RR, Schullek J. Cleavage of human von Willebrand factor by platelet calcium-activated protease. Blood 1985; 65: 352-6.
    PubMedGoogle Scholar
  • 50 Berkowitz SD, Nozaki H, Titani K, Murachi T, Plow EF, Zimmerman TS. Evidence that calpains and elastase do not produce the von Willebrand factor fragments present in normal plasma and IIA von Willebrand disease. Blood 1988; 72: 721-7.
    PubMedGoogle Scholar
  • 51 Hamilton KK, Fretto JL, Grierson DS, McKee PA. Effects of plasmin on von Willebrand factor multimers. Degradation in vitro and stimulation of release in vivo. J Clin Invest 1985; 76: 261-70.
    CrossrefPubMedGoogle Scholar
  • 52 Bellinger DA, Nichols TC, Read MS, Reddick RL, Lamb MA, Brinkhous KM, Evatt BL, Griggs TR. Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor. Proc Natl Acad Sci USA 1987; 84: 8100-4.
    CrossrefPubMedGoogle Scholar
  • 53 Denis C, Williams JA, Lu X, Meyer D, Baruch D. Solid-phase von Willebrand Factor contains a conformationally active RGD motif that mediates endothelial cell adhesion through the αVβ3 receptor. Blood 1993; 82: 3622-30.
    PubMedGoogle Scholar
  • 54 Gerrard JM, Phillips DR, Rao GHR, Plow EF, Walz DA, Ross R, Harker LA, White JG. Biochemical studies of two patients with the gray platelet syndrome. Selective deficiency of platelet alpha granules. J Clin Invest 1980; 66: 102-9.
    CrossrefPubMedGoogle Scholar
  • 55 Bihour C, Durrieu-Jaïs C, Nurden P, Nurden AT. Flow cytometry reveals activated GPIIb-IIIa complexes on platelets from patients undergoing thrombolytic therapy after acute myocardial infarction. Blood Coagul Fibrinolysis 1995; 6: 395-410.
    CrossrefPubMedGoogle Scholar